Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Potkul

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
Journal of Ovarian Research|May 31, 2018
Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancerMaureen L Drakes, Swati Mehrotra, Monica Aldulescu, et al.
La Clinica Terapeutica|October 21, 2006
Chronotherapy of ovarian cancer: effect on blood variables and serum cytokines. A case reportE L Kanabrocki, R C Hermida, M Torossov, et al.
Cytokines and Molecular Therapy|September 1, 1996
Efficacy of current molecular cytogenetic protocols for the diagnosis of chromosome aberrations in tumor specimensP Lichter, K Fischer, S Joos, et al.
Gynecologic Oncology|September 10, 1999
Phase II trial of oral etoposide in recurrent or refractory endometrial adenocarcinoma: a southwest oncology group studyE A Poplin, P Y Liu, J E Delmore, et al.
Brachytherapy|May 16, 2018
Comparison of dosimetric and clinical outcomes between short- and long-channel cylinder applicators for vaginal brachytherapy in intermediate- and high-risk endometrial cancerMichael Z Kharouta, Nghia Pham, Karina Nieto, et al.
Brachytherapy|November 2, 2017
Early outcomes and impact of a hybrid IC/IS applicator for a new MRI-based cervical brachytherapy programMatthew M Harkenrider, Murat Surucu, Grant Harmon, et al.
Cancers|May 4, 2026
Outcomes of an Alpha-DC-1 Dendritic Cell-Based Vaccine Clinical Trial in Patients with Low-Tumor-Burden High-Risk Ovarian CarcinomaPatrick J Stiff, Cheryl M Czerlanis, Ronald K Potkul, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2005
Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancerSusana Campos, Oday Hamid, Michael V Seiden, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 22, 1998
PBLs of early breast carcinoma patients with a high nuclear grade tumor unlike PBLs of cervical carcinoma patients do not show a decreased TCR zeta expression but are functionally impairedJ D Nieland, K Loviscek, K Kono, et al.
Journal of Contemporary Brachytherapy|May 24, 2017
How one institution overcame the challenges to start an MRI-based brachytherapy program for cervical cancerMatthew M Harkenrider, Steven M Shea, Abbie M Wood, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Journal of Ovarian Research|May 31, 2018
Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancerMaureen L Drakes, Swati Mehrotra, Monica Aldulescu, et al.
La Clinica Terapeutica|October 21, 2006
Chronotherapy of ovarian cancer: effect on blood variables and serum cytokines. A case reportE L Kanabrocki, R C Hermida, M Torossov, et al.
Cytokines and Molecular Therapy|September 1, 1996
Efficacy of current molecular cytogenetic protocols for the diagnosis of chromosome aberrations in tumor specimensP Lichter, K Fischer, S Joos, et al.
Gynecologic Oncology|September 10, 1999
Phase II trial of oral etoposide in recurrent or refractory endometrial adenocarcinoma: a southwest oncology group studyE A Poplin, P Y Liu, J E Delmore, et al.
Brachytherapy|May 16, 2018
Comparison of dosimetric and clinical outcomes between short- and long-channel cylinder applicators for vaginal brachytherapy in intermediate- and high-risk endometrial cancerMichael Z Kharouta, Nghia Pham, Karina Nieto, et al.
Brachytherapy|November 2, 2017
Early outcomes and impact of a hybrid IC/IS applicator for a new MRI-based cervical brachytherapy programMatthew M Harkenrider, Murat Surucu, Grant Harmon, et al.
Cancers|May 4, 2026
Outcomes of an Alpha-DC-1 Dendritic Cell-Based Vaccine Clinical Trial in Patients with Low-Tumor-Burden High-Risk Ovarian CarcinomaPatrick J Stiff, Cheryl M Czerlanis, Ronald K Potkul, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2005
Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancerSusana Campos, Oday Hamid, Michael V Seiden, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 22, 1998
PBLs of early breast carcinoma patients with a high nuclear grade tumor unlike PBLs of cervical carcinoma patients do not show a decreased TCR zeta expression but are functionally impairedJ D Nieland, K Loviscek, K Kono, et al.
Journal of Contemporary Brachytherapy|May 24, 2017
How one institution overcame the challenges to start an MRI-based brachytherapy program for cervical cancerMatthew M Harkenrider, Steven M Shea, Abbie M Wood, et al.
Pageof 7